Evaluating the Role of Neoadjuvant Endocrine Therapy in Breast Cancer
Sara M. Tolaney, MD, MPH, discusses the evolving role of neoadjuvant endocrine therapy in the breast cancer space. She says there is particular interest in using this therapy in patients with HER2-positive and triple-negative breast cancer, but it can be more challenging in patients with ER-positive disease.
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, discusses the evolving role of neoadjuvant endocrine therapy in the breast cancer space. She says there is particular interest in using this therapy in patients with HER2-positive and triple-negative breast cancer, but it can be more challenging in patients with ER-positive disease.
Using the responses of preoperative therapy can help physicians adapt adjuvant therapy regimens and improve responses in patients, Tolaney says. However, patients with ER+ disease do not achieve pathologic complete responses as often in this setting. The development of surrogate biomarkers helps in learning how to use neoadjuvant endocrine therapy.
Neoadjuvant endocrine therapy has been associated with improved rates of breast conservation. This therapy is also less toxic than neoadjuvant chemotherapy. The biggest challenge with this therapy is selecting which patients will benefit better from the endocrine therapy versus chemotherapy, says Tolaney.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
